- Home
- VTVT vs BDSX Comparison
VTVT vs BDSX Comparison
Compare VTVT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- BDSX
- Stock Information
- Founded
- VTVT 2015
- BDSX 2005
- Country
- VTVT United States
- BDSX United States
- Employees
- VTVT N/A
- BDSX N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- BDSX Precision Instruments
- Sector
- VTVT Health Care
- BDSX Health Care
- Exchange
- VTVT Nasdaq
- BDSX Nasdaq
- Market Cap
- VTVT 47.9M
- BDSX 53.2M
- IPO Year
- VTVT 2015
- BDSX 2020
- Fundamental
- Price
- VTVT $19.02
- BDSX $0.41
- Analyst Decision
- VTVT Strong Buy
- BDSX Strong Buy
- Analyst Count
- VTVT 2
- BDSX 5
- Target Price
- VTVT $35.50
- BDSX $1.75
- AVG Volume (30 Days)
- VTVT 2.9K
- BDSX 4.5M
- Earning Date
- VTVT 08-12-2025
- BDSX 10-31-2025
- Dividend Yield
- VTVT N/A
- BDSX N/A
- EPS Growth
- VTVT N/A
- BDSX N/A
- EPS
- VTVT N/A
- BDSX N/A
- Revenue
- VTVT $17,000.00
- BDSX $76,556,000.00
- Revenue This Year
- VTVT N/A
- BDSX $18.80
- Revenue Next Year
- VTVT N/A
- BDSX $27.76
- P/E Ratio
- VTVT N/A
- BDSX N/A
- Revenue Growth
- VTVT N/A
- BDSX 25.70
- 52 Week Low
- VTVT $12.62
- BDSX $0.17
- 52 Week High
- VTVT $26.99
- BDSX $1.86
- Technical
- Relative Strength Index (RSI)
- VTVT 70.74
- BDSX 46.95
- Support Level
- VTVT $15.79
- BDSX $0.41
- Resistance Level
- VTVT $21.01
- BDSX $0.53
- Average True Range (ATR)
- VTVT 0.84
- BDSX 0.05
- MACD
- VTVT 0.32
- BDSX -0.00
- Stochastic Oscillator
- VTVT 69.17
- BDSX 19.56
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.